Contract manufacturing organisation (CMO) KBI Biopharma and cell line development company Selexis have opened an integrated facility in Geneva, Switzerland.
The integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell manufacturing in a single location. The facility will leverage the companies’ expertise and end-to-end services for biomanufacturing clients.
KBI and Selexis hope that the expansion will help them deliver client programmes through increased quality, efficiency, and time savings across a diverse portfolio of molecule formats. The facility will provide cell line transfection through cGMP drug manufacturing with Selexis’ high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.
The expanded facility in now operational and the companies expect there to be over 200 technical positions in developmnetand quality assurance to be filled.
Official comments
“This expansion in Geneva will provide our global clients with streamlined capabilities to support mammalian-based therapies,” said Mark W. Womack, Chief Executive Officer for KBI Biopharma and Selexisw. “With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.”
“This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe,” he added.
“We have always been a science-driven, customer-centric company. This expansion in Geneva helps our clients optimise their complex biomanufacturing processes under accelerated timelines,” said Ulrich Valley, Senior Vice President, Operations & Site Head, KBI Biopharma, Geneva.
